Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DataMEDS AIMEDS +4.58% Debt-to-Equity is -1.68 as of Jun. 2026. The stock has 7 warning signs investors should review. Among 102 Medical Distribution companies, DataMEDS AI ranks worse than 980391.18% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for DataMEDS AI's Debt-to-Equity or its related term are showing as below:
MEDS'
s Debt-to-Equity Range Over the Past 10 Years
Min: -24.04 Med: -0.12 Max: 27.48
Current: -1.68
During the past 4 years, the highest Debt-to-Equity Ratio of DataMEDS AI was 27.48. The lowest was -24.04. And the median was -0.12.
MEDS's Debt-to-Equity is not ranked
in the Medical Distribution industry.
Industry Median: 0.46
vs MEDS: -1.68
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
DataMEDS AI Debt-to-Equity Related Terms
DataMEDS AI Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for DataMEDS AI's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, DataMEDS AI's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DataMEDS AI Debt-to-Equity vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, DataMEDS AI's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where DataMEDS AI's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DataMEDS AI (MEDS) has a Debt-to-Equity of -1.68 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on DataMEDS AI and its competitors. According to the industry distribution chart, DataMEDS AI ranks #999999 out of 102 companies in the Medical Distribution industry.
Is DataMEDS AI's Debt-to-Equity too high?
DataMEDS AI's current Debt-to-Equity is -1.68. Based on the distribution chart, DataMEDS AI ranks #999999 out of 102 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers.
How does DataMEDS AI's Debt-to-Equity compare to SNYR and MCK?
According to the Medical Distribution industry distribution chart, DataMEDS AI ranks #999999 out of 102 companies for Debt-to-Equity. This places DataMEDS AI in the lower half of its industry. The industry median Debt-to-Equity is 0.46. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Distribution company?
The median Debt-to-Equity among Medical Distribution companies is 0.46, based on 102 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on DataMEDS AI and its competitors. For the Medical Distribution industry, the median Debt-to-Equity is 0.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DataMEDS AI's current Debt-to-Equity is -1.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DataMEDS AI stock overvalued right now?
DataMEDS AI (MEDS) has a current Debt-to-Equity of -1.68. The current Debt-to-Equity is -1.68. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For DataMEDS AI (MEDS), the current Debt-to-Equity is -1.68 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Wellgistics Health Inc is a healthcare technology and pharmaceutical logistics company. It simplifies the logistics of prescription fulfillment from the manufacturer and provider to the patient. The company seeks to be a micro health ecosystem, with a portfolio comprising a pharmacy, wholesale operations, and a technology division that provides a novel platform for hub and clinical services. It is focused on improving the lives of patients while delivering solutions for pharmacies, providers, pharmaceutical manufacturers, and payors.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEDS has been successfully added to your 
